Patients with inflammatory bowel disease who had three or four specific acetyltransferases in their gut microbiota had a threefold higher risk for 5-ASA treatment failure.
Multicancer early detection tests are finally a reality and could be a potential game changer because may be able to screen for up to 50 different cancers in asymptomatic individuals with one blood draw.
Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.
Patients with ctDNA alterations who received targeted therapy on the basis of these alterations survived longer than patients who did not receive targeted therapy.
Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.